Vitamin B12 supplementation in end stage renal diseases: a sys-tematic review
Authors
Abstract:
Background :Hyperhomocysteinemia is a risk factor for cardiovascular disease particularly in patients with end stage renal disease (ESRD). Vitamin B12 supplementation on its own still remains as a controversial issue for clinicians in decreasing the level of homcysteine in this group of patients. Methods : Using all randomized controlled trials (RCTs), clinical trials and pre-post-trial studies found during January 1999 to March 2014, we conducted a systematic review which assessed the effects of vitamin B12 in decreasing homocysteine levels in patients with ESRD. Results : The findings of this study revealed that, overall, the greatest effect of B12 supplementation on decreasing homocysteine levels in patients with ESRDs occurred when it was combined with folate supplementation. It was also demonstrated that injection treatments might be more beneficial than oral intake treatments. Conclusion : More rigorous studies are needed to draw a firm conclusion about B12 therapy and the level of homocyteine in patients with ESRD.
similar resources
vitamin b12 supplementation in end stage renal diseases: a sys-tematic review
background :hyperhomocysteinemia is a risk factor for cardiovascular disease particularly in patients with end stage renal disease (esrd). vitamin b12 supplementation on its own still remains as a controversial issue for clinicians in decreasing the level of homcysteine in this group of patients. methods : using all randomized controlled trials (rcts), clinical trials and pre-post-trial studi...
full textVitamin B12 supplementation in end stage renal diseases: a systematic review
BACKGROUND Hyperhomocysteinemia is a risk factor for cardiovascular disease particularly in patients with end stage renal disease (ESRD). Vitamin B12 supplementation on its own still remains as a controversial issue for clinicians in decreasing the level of homcysteine in this group of patients. METHODS Using all randomized controlled trials (RCTs), clinical trials and pre-post-trial studies ...
full textParenteral vitamin B12 reduces hyperhomocysteinemia in end-stage renal disease.
OBJECTIVE The authors found considerably lower plasma total homocysteine (tHcy) concentrations in patients with end-stage renal disease (ESRD) on maintenance hemodialysis, who routinely received high-dose parenteral vitamin B12, than in comparable patients receiving much higher doses of folic acid but only replacement-dose oral vitamin B12. They therefore sought prospective evidence that high-d...
full textPrevalence of infectious diseases in patients with end stage renal disease in Gorgan City in Iran
Background: The mortality rate of sepsis and pneumonia is higher in end-stage renal disease (ESRD) patients than in the general population. Bacterial infections are the most common cause of hospitalization in dialysis patients and the most common source of bacteremia is vascular access in these patients. The aim of this study was to determine the prevalence of infectious causes of hospitalizati...
full textVitamin B12 in Health: A Review
Vitamin B-12 was discovered in 1948 in the liver of animals, as a results of three scientists–Whipple, Minot and Murphy, looking into what caused pernicious anemia, which until the time of their discovery was deadly. In 1934 they discovered that a liver, a very rich source of B12, could be used to treat pernicious anemia (inability of the bloodstream to carry oxygen). When the discovery was mad...
full textSerum vitamin B12 in renal failure.
The serum vitamin B(12) level was abnormally high in 14 out of 32 cases of renal failure. This was probably due to impaired excretion of the vitamin, but the results of measurements of the rate of excretion of radioactive vitamin B(12) did not provide unequivocal evidence on this point; other possible explanations are discussed. Renal failure must be added to the causes of high serum B(12) levels.
full textMy Resources
Journal title
volume 29 issue 1
pages 54- 61
publication date 2015-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023